Literature DB >> 28550185

Low-dose methotrexate in myeloproliferative neoplasm models.

Kavitha Chinnaiya1, Michelle A Lawson2, Sally Thomas1, Marie-Therese Haider2, Jenny Down2, Andrew D Chantry2, David Hughes3, Antony Green4, Jon R Sayers5, John A Snowden2,6, Martin P Zeidler7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28550185      PMCID： PMC5685234          DOI： 10.3324/haematol.2017.165738

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

Review 1.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

Authors:  Peter Jones; R Ian Storer; Yogesh A Sabnis; Florian M Wakenhut; Gavin A Whitlock; Katherine S England; Takasuke Mukaiyama; Christoph M Dehnhardt; Jotham W Coe; Steve W Kortum; Jill E Chrencik; David G Brown; Rhys M Jones; John R Murphy; Thean Yeoh; Paul Morgan; Iain Kilty
Journal:  J Med Chem       Date:  2017-01-04       Impact factor: 7.446

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

Review 4.  Mechanisms of Jak/STAT signaling in immunity and disease.

Authors:  Alejandro V Villarino; Yuka Kanno; John R Ferdinand; John J O'Shea
Journal:  J Immunol       Date:  2015-01-01       Impact factor: 5.422

5.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Authors:  Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

6.  Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.

Authors:  F Lange; E Bajtner; C Rintisch; K S Nandakumar; U Sack; R Holmdahl
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

7.  Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa.

Authors:  Marguerite S Joly; Roderick P Martin; Shibani Mitra-Kaushik; Lucy Phillips; Alida D'Angona; Susan M Richards; Alexandra M Joseph
Journal:  J Immunol       Date:  2014-09-10       Impact factor: 5.422

8.  Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.

Authors:  Ruben Mesa; Srdan Verstovsek; Jean-Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Huiling Zhen; Mark M Jones; Shreekant Parasuraman; Jingjin Li; Isabelle Côté; Dany Habr; Alessandro M Vannucchi
Journal:  Eur J Haematol       Date:  2016-01-03       Impact factor: 2.997

Review 9.  Recent advances in understanding myelofibrosis and essential thrombocythemia.

Authors:  William Vainchenker; Stefan N Constantinescu; Isabelle Plo
Journal:  F1000Res       Date:  2016-04-19

10.  JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Authors:  Juan Li; David G Kent; Anna L Godfrey; Harriet Manning; Jyoti Nangalia; Athar Aziz; Edwin Chen; Kourosh Saeb-Parsy; Juergen Fink; Rachel Sneade; Tina L Hamilton; Dean C Pask; Yvonne Silber; Xiaodong Zhao; Cedric Ghevaert; Pentao Liu; Anthony R Green
Journal:  Blood       Date:  2014-04-01       Impact factor: 22.113
View more
  3 in total

Review 1.  JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.

Authors:  Elisa Gremese; Stefano Alivernini; Barbara Tolusso; Martin P Zeidler; Gianfranco Ferraccioli
Journal:  J Leukoc Biol       Date:  2019-07-16       Impact factor: 4.962

2.  Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.

Authors:  Jason Ptacek; Rachael E Hawtin; Dongmei Sun; Brent Louie; Erik Evensen; Barbara B Mittleman; Alessandra Cesano; Guy Cavet; Clifton O Bingham; Stacey S Cofield; Jeffrey R Curtis; Maria I Danila; Chander Raman; Richard A Furie; Mark C Genovese; William H Robinson; Marc C Levesque; Larry W Moreland; Peter A Nigrovic; Nancy A Shadick; James R O'Dell; Geoffrey M Thiele; E William St Clair; Christopher C Striebich; Matthew B Hale; Houman Khalili; Franak Batliwalla; Cynthia Aranow; Meggan Mackay; Betty Diamond; Garry P Nolan; Peter K Gregersen; S Louis Bridges
Journal:  PLoS One       Date:  2021-01-14       Impact factor: 3.240

3.  Crystal structure of the human PRPK-TPRKB complex.

Authors:  Jian Li; Xinli Ma; Surajit Banerjee; Hanyong Chen; Weiya Ma; Ann M Bode; Zigang Dong
Journal:  Commun Biol       Date:  2021-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.